Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript - Thomson StreetEvents

Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript

Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript - Thomson StreetEvents
Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript
Published Mar 30, 2020
12 pages (8422 words) — Published Mar 30, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of IMVT.OQ conference call or presentation 30-Mar-20 12:30pm GMT

  
Brief Excerpt:

...Operator Good morning. My name is Sherry, and I will serve as your conference call operator. (Operator Instructions) As a reminder, this call is being recorded. Joining me on today's call will be Dr. Pete Salzmann, Chief Executive Officer of Immunovant. Before we begin, I would like to remind everyone that today's conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to various risks, uncertainties, assumptions, known or unknown, which could cause actual results to vary materially from those indicated or anticipated. For more information, investors are encouraged to review Immunovant's most recent quarterly report on Form 10-Q filed with the SEC on February 14, 2020. I would now like to turn the call over to Dr. Pete Salzmann. Thank you, Dr. Salzmann, you may begin. Peter Salzmann ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Immunovant Inc
Ticker
IMVT.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Immunovant Inc Q1 2022 Earnings Call Transcript – 2021-08-09 – US$ 54.00 – Edited Transcript of IMVT.OQ earnings conference call or presentation 9-Aug-21 12:00pm GMT

Immunovant, Inc. - Special Call Transcript – 2021-02-02 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 2-Feb-21 1:00pm GMT

Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript – 2020-11-12 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 12-Nov-20 3:15pm GMT

Immunovant, Inc. - Special Call Transcript – 2020-08-25 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 25-Aug-20 12:30pm GMT

Immunovant Inc Annual Shareholders Meeting Transcript – 2020-08-19 – US$ 54.00 – Edited Transcript of IMVT.OQ shareholder or annual meeting 19-Aug-20 5:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript" Mar 30, 2020. Alacra Store. May 18, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-Discusses-Initial-Results-From-ASCEND-GO-1-An-Open-Label-Phase-2a-Trial-Of-IMVT-1401-In-Thyroid-Eye-Disease-And-Provides-Corporate-Update-T13166233>
  
APA:
Thomson StreetEvents. (2020). Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript Mar 30, 2020. New York, NY: Alacra Store. Retrieved May 18, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-Discusses-Initial-Results-From-ASCEND-GO-1-An-Open-Label-Phase-2a-Trial-Of-IMVT-1401-In-Thyroid-Eye-Disease-And-Provides-Corporate-Update-T13166233>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.